ClinicalTrials.gg
CompletedNCT02287272Updated Oct 29, 2021

Drug-drug Interaction Study of CHF5993 With Cimetidine

A Phase 1 interventional study of CHF 5993 pMDI and Cimetidine plus CHF5993 pMDI in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Enrollment
50th of 59
25 · median 65
Started
2014
with 7 others
Phase 1
21 of 68
none open now
Registered
26th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 50th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2014, is one of 21 in phase 1, and was the 26th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993 (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of the organic cation transport in the kidneys), by comparing the systemic exposure (AUC0-t) of Glycopyrronium Bromide (GB), after a single dose of the fixed combination CHF 5993 pMDI administered alone or at steady-state of Cimetidine

Read the detailed description

the safety and tolerability of study treatments based on evaluation of vital signs, electrocardiograms and clinical laboratory assessments will be also evaluated.

03

Conditions studied

  • COPD

Keywords

  • COPD- cimetidine- drug-drug interaction
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedure;
  2. Male and female healthy volunteers aged 18-45 years inclusive;
  3. Male subjects with female partner of : they or their partner must be willing to use (at least) one or more reliable methods of (see exclusion criterion n.1 for details*) from the time of dose administration and until the end of the study. Male subjects must not donate sperm for 90 days after the last dose of study drug. Male subjects with partners of non-childbearing potential are not required to use contraception;
  4. Able to understand the study procedures, the risks involved and ability to be trained to correctly use the devices;
  5. (BMI) between 18.0 and 30.0 kg/m2 inclusive;
  6. A serum creatinine within the normal range (0,7-1,2 mg/dL) and an >80 mL/min/1.73 m2;
  7. Non- or ex-smokers who smoked \< 5 pack years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year;
  8. Good physical and mental status, determined on the basis of the medical history and a general clinical examination;

Exclusion criteria

Exclusion Criteria:

  1. Female subjects: pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) UNLESS they meet the following definition of : 12 months of natural (spontaneous) documented amenorrhea or are willing to use one or more of the following reliable *methods of :

    1. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy for females; vasectomy for males)
    2. hormonal contraception (implantable, patch, oral), intrauterine device (IUD) or intrauterine system (IUS)
    3. barrier methods (male or female condom, diaphragm, sponge, cervical cap).
  2. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;
  3. Positive HIV1 or HIV2 serology;
  4. Positive results from the Hepatitis serology which indicates acute or chronic or ;
  5. History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;
  6. An abnormal triplicate 12-lead (QRS> 120 msec, PR> 220 msec, HR \< 40 bpm, HR > 110 bpm) at screening or at randomization;
  7. Subjects whose electrocardiogram (12-lead ECG) shows >450 ms for males and >470 for females at screening or at randomization;
  8. Subjects whose DBP is higher than 90 mmHg or SBP is higher than 140 mmHg at screening or at randomization;
  9. Subjects who received any new drug, or participated in clinical study within the last 8 weeks before screening;
  10. History of to M3 Antagonists, β2-agonist, or any of the contained in any of the formulations used in the trial;
  11. Treatment within the previous 3 months before the screening visit until the end of the study procedures in the last treatment period with any drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);
  12. Subjects who refuse to abstain from alcohol or xanthine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to each intake of study medication until the end of confinement at the clinical centre;
  13. Heavy caffeine drinker (> 5 cups or glasses of caffeinated beverages e.g., coffee, tea, cola per day);
  14. Subjects who have a positive urine test for cotinine at screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Treatment period R

    single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)

    Drug: CHF 5993 pMDI

  • Active comparator
    Treatment period T

    Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)

    Drug: Cimetidine plus CHF5993 pMDI

Interventions

  • 4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB

  • DrugCimetidine plus CHF5993 pMDI

    Drug pages: Cimetidine · CHF5993

    Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) of Glycopyrronium Bromide

    Time frame: pre-dose, 5, 10,15,30min, 1,2,4,6,8,12hr post-dose

Secondary outcomes

  1. Other pharmacokinetic parameters for Glycopyrronium Bromide

    Area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Glycopyrronium Bromide

    Time frame: pre-dose-72hr post-dose

  2. Other pharmacokinetic parameters for Formoterol

    Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Formoterol

    Time frame: pre-dose-24hr post dose

  3. Other pharmacokinetic parameters for B17MP

    Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of B17MP

    Time frame: pre-dose- 72hr post-dose

07

Study locations

1 site
  • Life Science Services SGS Belgium NV
    Antwerp, 2060, Belgium
08

References and documents

Publications

  • Mariotti F, Ciurlia G, Spaccapelo L, Muraro A, Acerbi D. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):269-279. doi: 10.1007/s13318-016-0345-2. PubMed 27209586 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Jul 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2014
First posted
Nov 10, 2014
Start
May 2014
Primary completionActual
Jul 2014
CompletionActual
Sep 2014
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02287272
Responsible party
Sponsor
First posted
Nov 10, 2014
Start date
May 2014
Primary completion
Jul 2014
Completion
Sep 2014
Last update
Oct 29, 2021

Study contacts

Wouter Haazen, MD
principal investigator · Life Science Services SGS Belgium NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHF5993 · Cimetidine

Start the discussion